Want to see GB:POLB full AI Analyst Report?
POLB Stock Chart & Stats
8.60 p
0.00 p(0.00%)
At close: 4:00 PM EDT
8.60 p
0.00 p(0.00%)
Day’s Range― - ―
52-Week Range3.30 p - 9.20 p
Previous CloseN/A
Volume885.20K
Average Volume (3M)2.63M
Market Cap
£62.98M
Enterprise Value20.18 p
Total Cash (Recent Filing)£7.71M
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)―
Beta0.54
Next Earnings
Sep 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding763,437,130
10 Day Avg. Volume2,437,598
30 Day Avg. Volume2,627,520
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)2.80
Price to Sales (P/S)0.00
P/FCF Ratio-4.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical And Regulatory ReadinessPOLB 001 has moved beyond planning into a regulated, operationally ready clinical study with sites, CRO support and trial supply arranged. This reduces execution friction and creates a defined path to interim data that could materially de-risk the lead program over the next several quarters.
Strong Early Target Engagement And IPDose-dependent cytokine suppression provides meaningful early evidence that POLB 001 engages its intended inflammatory pathway without immunosuppression. Combined with the company’s stated patent coverage to at least 2044, this supports potential differentiation and longer-lived asset protection if clinical translation succeeds.
Funded Near-term Development RunwayThe available cash and grant support give Poolbeg capacity to advance its lead clinical program and prepare additional development work without immediate debt pressure. Runway into 2027 allows time to generate clinical evidence and pursue licensing discussions before larger downstream funding needs arise.
Bears Say
Pre-revenue And Persistent LossesPoolbeg has not yet produced commercial revenue to offset research and operating costs, while losses remain material and persistent. Until a candidate is partnered on meaningful terms or reaches commercialization, the company’s earnings profile will remain dependent on advancing assets ahead of future monetization.
Sustained Cash Burn And Equity ErosionOngoing operating cash consumption and the shrinking equity base reduce financial flexibility despite the absence of reported debt. Continued development will require disciplined spending and successful partnering or further capital, creating a durable funding constraint as programs move toward larger trials.
Early Trial Design Limits Evidence StrengthThe initial TOPICAL study can identify a clinical signal, but its small, uncontrolled design limits the ability to separate treatment effects from patient or disease variability. Positive interim data may therefore need confirmation in larger controlled studies before regulators or partners support broad commercialization.
Poolbeg Pharma Ltd. News
POLB FAQ
What was Poolbeg Pharma Ltd.’s price range in the past 12 months?
Poolbeg Pharma Ltd. lowest share price was 3.30 p and its highest was 9.20 p in the past 12 months.
What is Poolbeg Pharma Ltd.’s market cap?
Poolbeg Pharma Ltd.’s market cap is £62.98M.
When is Poolbeg Pharma Ltd.’s upcoming earnings report date?
Poolbeg Pharma Ltd.’s upcoming earnings report date is Sep 08, 2026 which is tomorrow.
How were Poolbeg Pharma Ltd.’s earnings last quarter?
Poolbeg Pharma Ltd. released its earnings results on Apr 28, 2026. The company reported -0.005 p earnings per share for the quarter.
Is Poolbeg Pharma Ltd. overvalued?
According to Wall Street analysts Poolbeg Pharma Ltd.’s price is currently Overvalued.
Does Poolbeg Pharma Ltd. pay dividends?
Poolbeg Pharma Ltd. does not currently pay dividends.
What is Poolbeg Pharma Ltd.’s EPS estimate?
Poolbeg Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Poolbeg Pharma Ltd. have?
Poolbeg Pharma Ltd. has 763,437,130 shares outstanding.
What happened to Poolbeg Pharma Ltd.’s price movement after its last earnings report?
Poolbeg Pharma Ltd. reported an EPS of -0.005 p in its last earnings report. Following the earnings report the stock price went down -3.371%.
Which hedge fund is a major shareholder of Poolbeg Pharma Ltd.?
Currently, no hedge funds are holding shares in GB:POLB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Poolbeg Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth £250.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.98%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company based in the United Kingdom, focused on developing treatments for infectious diseases. Its pipeline features several key programs: POLB 001, a p38 MAP Kinase inhibitor intended for severe influenza; POLB 002, a pioneering, in-licensed RNA-based immunotherapy administered intranasally to combat respiratory virus infections; and POLB 003, an intramuscular vaccine aimed at preventing Melioidosis. Beyond specific therapeutic candidates, Poolbeg also holds licensed access to advanced micro- and nanoencapsulation technology for an oral vaccine delivery system designed to stimulate gut immunity. The company further advances its research through an artificial intelligence-powered drug program. Additionally, Poolbeg is developing a biomarker platform to identify individuals at high risk of severe disease, alongside a model-derived vaccine discovery platform to pinpoint novel vaccine candidates. Incorporated in 2021, Poolbeg Pharma plc is headquartered in London.
Technical Analysis
ImmuPharma
―
Sareum Holdings
―
HemoGenyx Pharmaceuticals Plc
―
Open Orphan Plc
―
Aptamer Group Plc
―